Skip to main content
Figure 2 | BMC Endocrine Disorders

Figure 2

From: Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

Figure 2

Decline in IGF-1 levels with PEG treatment. Baseline and follow up mean values with 95% confidence intervals reported in randomised [7] and non-randomised studies. The duration of treatment in the 5 phases of the Jorgensen study [19] was 2 to 4 weeks, 8 weeks, 6 weeks, 6 weeks and 12 weeks. Dose of PEG in the RCT extension [8] and in Schreiber [21] varied according to patient response. Figure compiled from published data [7, 8, 19, 21] with the addition of 95% CI.

Back to article page